Gareth J Morgan, PhD Hear my name
Research Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

PhD, University of Sheffield
BS, Imperial College London

Gareth Morgan, PhD is a Research Assistant Professor at the Chobanian and Avedisian School of Medicine. His research focuses on the molecular mechanisms of AL amyloidosis with the aim of developing new treatments for this disease.

Diversity, Equity, Inclusion and Accessibility

Doing science well is challenging because the questions that we ask are difficult. Otherwise, why would we bother? To be successful, researchers need a working environment where their ability to focus on scientific questions is not hindered by arbitrary barriers.
As a scientist and mentor, my role is to direct and facilitate the work carried out by my colleagues and to support their professional development. Science thrives where diverse viewpoints and perspectives are brought to bear on a problem, and everyone has the potential to develop their ability to design, execute and analyze experiments.
We strive to create a welcoming, supportive environment where individuals’ needs are addressed and anyone with an enquiring mind and willingness to learn is able to work to the limits of their own ability. We will endeavor to support colleagues with whatever accommodations they need to achieve their goals. Anyone with an interest in amyloidosis is welcome to join the lab, regardless of age, race, ethnicity, beliefs, sexual or gender orientation, disability or other factors. In turn, we expect a high standard of professionalism and support for other team members and the broader community.

Boston University
BU-BMC Cancer Center

Boston University
Amyloidosis Center

Boston University
Genome Science Institute

Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Establishing Strategies to Ameliorate Amyloid Pathology in Light Chain Amyloidosis
07/01/2020 - 06/30/2024 (Subcontract PI)
The Scripps Research Institute NIH NIDDK
5R01 DK107604-07

Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge
01/01/2022 - 12/31/2023 (PI)
Johnson & Johnson


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Wong S, West ME, Morgan GJ. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains. Protein Sci. 2024 Mar; 33(3):e4871. PMID: 38100259; PMCID: PMC10868443; DOI: 10.1002/pro.4871;
  2. Chen X, Varma G, Davies F, Morgan G. Approach to High-Risk Multiple Myeloma. Hematol Oncol Clin North Am. 2024 Apr; 38(2):497-510. PMID: 38195306
  3. Wong S, West ME, Morgan GJ. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains. bioRxiv. 2023 Aug 28. PMID: 37693524; PMCID: PMC10491100; DOI: 10.1101/2023.08.28.555139;
  4. Yan NL, Morgan GJ, Petrassi HM, Wilson IA, Kelly JW. Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis. Curr Opin Chem Biol. 2023 Aug; 75:102319. PMID: 37279624; PMCID: PMC10523890; DOI: 10.1016/j.cbpa.2023.102319;
  5. Nau A, Shen Y, Sanchorawala V, Prokaeva T, Morgan GJ. Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data. Front Immunol. 2023; 14:1167235.View Related Profiles. PMID: 37143670; PMCID: PMC10151772; DOI: 10.3389/fimmu.2023.1167235;
  6. Yan NL, Nair R, Chu A, Wilson IA, Johnson KA, Morgan GJ, Kelly JW. Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. Bioorg Med Chem Lett. 2022 03 15; 60:128571. PMID: 35065233; PMCID: PMC8857066; DOI: 10.1016/j.bmcl.2022.128571;
  7. Morgan GJ. Transient disorder along pathways to amyloid. Biophys Chem. 2022 02; 281:106711. PMID: 34839162
  8. Morgan GJ, Buxbaum JN, Kelly JW. Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato. 2021 Dec; 2(4):645-659. PMID: 35757512; PMCID: PMC9218996; DOI: 10.3390/hemato2040042;
  9. Morgan GJ. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis. Molecules. 2021 Jun 11; 26(12). PMID: 34208058; PMCID: PMC8230685; DOI: 10.3390/molecules26123571;
  10. Yan NL, Santos-Martins D, Nair R, Chu A, Wilson IA, Johnson KA, Forli S, Morgan GJ, Petrassi HM, Kelly JW. Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. J Med Chem. 2021 05 13; 64(9):6273-6299. PMID: 33939422; PMCID: PMC8428256; DOI: 10.1021/acs.jmedchem.1c00339;
Showing 10 of 29 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 29 publications over 17 distinct years, with a maximum of 4 publications in 2021

Contact for Mentoring:
Morgan's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department